Cargando…
The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and re...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494852/ https://www.ncbi.nlm.nih.gov/pubmed/37004241 http://dx.doi.org/10.17305/bb.2023.8791 |
_version_ | 1785104786927910912 |
---|---|
author | Ridwansyah, Hastono Wijaya, Indra Bashari, Muhammad Hasan Sundawa Kartamihardja, Achmad Hussein Suryawathy Hernowo, Bethy |
author_facet | Ridwansyah, Hastono Wijaya, Indra Bashari, Muhammad Hasan Sundawa Kartamihardja, Achmad Hussein Suryawathy Hernowo, Bethy |
author_sort | Ridwansyah, Hastono |
collection | PubMed |
description | B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and refractory cases. Chidamide (tucidinostat) is a novel histone deacetylase inhibitor that can reverse this epigenetic imbalance and has been approved for the treatment of T-cell malignancies. However, the use of chidamide for B-NHL remains limited, and the lack of relevant literature exacerbates this limitation. We conducted this review to summarize the anticancer activity of chidamide against B-NHL and its clinical applications to overcome drug resistance. This systematic review was conducted according to the PRISMA 2020 guidelines, using some keyword combinations from MEDLINE and EBSCO. The inclusion and exclusion criteria were also defined. Of the 131 records retrieved from databases, 16 were included in the review. Nine articles revealed that chidamide limited tumor progression by modifying the tumor microenvironment, stopping the cell cycle, inducing apoptosis and autophagy, and enhancing complement-dependent and antibody-dependent cell-mediated cytotoxicities. According to seven other studies, administering chidamide in combination with another existing therapeutic regimen may benefit not only patients with relapsed/refractory B-NHL but also those with newly diagnosed B-NHL. Chidamide plays many important roles in limiting B-NHL progression through epigenetic modifications. Thus, combining chidamide with other anticancer drugs may be more beneficial for patients with newly diagnosed and relapsed/refractory B-NHL. |
format | Online Article Text |
id | pubmed-10494852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-104948522023-10-01 The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review Ridwansyah, Hastono Wijaya, Indra Bashari, Muhammad Hasan Sundawa Kartamihardja, Achmad Hussein Suryawathy Hernowo, Bethy Biomol Biomed Review B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and refractory cases. Chidamide (tucidinostat) is a novel histone deacetylase inhibitor that can reverse this epigenetic imbalance and has been approved for the treatment of T-cell malignancies. However, the use of chidamide for B-NHL remains limited, and the lack of relevant literature exacerbates this limitation. We conducted this review to summarize the anticancer activity of chidamide against B-NHL and its clinical applications to overcome drug resistance. This systematic review was conducted according to the PRISMA 2020 guidelines, using some keyword combinations from MEDLINE and EBSCO. The inclusion and exclusion criteria were also defined. Of the 131 records retrieved from databases, 16 were included in the review. Nine articles revealed that chidamide limited tumor progression by modifying the tumor microenvironment, stopping the cell cycle, inducing apoptosis and autophagy, and enhancing complement-dependent and antibody-dependent cell-mediated cytotoxicities. According to seven other studies, administering chidamide in combination with another existing therapeutic regimen may benefit not only patients with relapsed/refractory B-NHL but also those with newly diagnosed B-NHL. Chidamide plays many important roles in limiting B-NHL progression through epigenetic modifications. Thus, combining chidamide with other anticancer drugs may be more beneficial for patients with newly diagnosed and relapsed/refractory B-NHL. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-10-01 2023-10-01 /pmc/articles/PMC10494852/ /pubmed/37004241 http://dx.doi.org/10.17305/bb.2023.8791 Text en © 2023 Ridwansyah et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ridwansyah, Hastono Wijaya, Indra Bashari, Muhammad Hasan Sundawa Kartamihardja, Achmad Hussein Suryawathy Hernowo, Bethy The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
title | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
title_full | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
title_fullStr | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
title_full_unstemmed | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
title_short | The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review |
title_sort | role of chidamide in the treatment of b-cell non-hodgkin lymphoma: an updated systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494852/ https://www.ncbi.nlm.nih.gov/pubmed/37004241 http://dx.doi.org/10.17305/bb.2023.8791 |
work_keys_str_mv | AT ridwansyahhastono theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT wijayaindra theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT basharimuhammadhasan theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT sundawakartamihardjaachmadhussein theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT suryawathyhernowobethy theroleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT ridwansyahhastono roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT wijayaindra roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT basharimuhammadhasan roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT sundawakartamihardjaachmadhussein roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview AT suryawathyhernowobethy roleofchidamideinthetreatmentofbcellnonhodgkinlymphomaanupdatedsystematicreview |